Nutriband Joins Russell Indexes, Highlighting AVERSA Fentanyl's Potential
Nutriband's inclusion in Russell indexes highlights its AVERSA Fentanyl's potential for $80M-$200M annual sales, offering investors a unique growth opportunity in the pharmaceutical sector.
This news is significant as it highlights Nutriband's growing influence in the pharmaceutical sector, particularly in the development of abuse-deterrent technologies. The inclusion in the Russell indexes not only provides Nutriband with increased visibility among investors but also underscores the importance of innovative solutions to combat drug abuse and misuse. For the public, this means safer pharmaceutical options are on the horizon, potentially reducing the risks associated with opioid abuse. For investors, it represents an opportunity to be part of a company that's making strides in addressing a critical public health issue.
Posted Jul 1, 2025, 4:20 PM UTC